$ISCO
International Stem Cell CORP

2021 Q1 Form 10-Q Financial Statement

#000156459021027997 Filed on May 14, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $1.658M $2.360M
YoY Change -29.75% 6.4%
Cost Of Revenue $615.0K $857.0K
YoY Change -28.24% 1.9%
Gross Profit $1.043M $1.503M
YoY Change -30.61% 9.15%
Gross Profit Margin 62.91% 63.69%
Selling, General & Admin $1.395M $1.655M
YoY Change -15.71% -24.01%
% of Gross Profit 133.75% 110.11%
Research & Development $215.0K $303.0K
YoY Change -29.04% -53.6%
% of Gross Profit 20.61% 20.16%
Depreciation & Amortization $66.00K $63.00K
YoY Change 4.76% -12.5%
% of Gross Profit 6.33% 4.19%
Operating Expenses $1.395M $303.0K
YoY Change 360.4% -53.6%
Operating Profit -$567.0K -$455.0K
YoY Change 24.62% -69.44%
Interest Expense $32.00K $28.00K
YoY Change 14.29% 100.0%
% of Operating Profit
Other Income/Expense, Net -$32.00K $82.00K
YoY Change -139.02% -85.93%
Pretax Income -$599.0K -$373.0K
YoY Change 60.59% -58.83%
Income Tax
% Of Pretax Income
Net Earnings -$599.0K -$373.0K
YoY Change 60.59% -58.83%
Net Earnings / Revenue -36.13% -15.81%
Basic Earnings Per Share
Diluted Earnings Per Share -$79.45K -$49.48K
COMMON SHARES
Basic Shares Outstanding 7.539M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.117M $708.0K
YoY Change 57.77% 14.19%
Cash & Equivalents $1.117M $708.0K
Short-Term Investments
Other Short-Term Assets $437.0K $434.0K
YoY Change 0.69% -9.58%
Inventory $1.055M $1.100M
Prepaid Expenses
Receivables $437.0K $1.138M
Other Receivables $0.00 $0.00
Total Short-Term Assets $3.046M $3.380M
YoY Change -9.88% -3.7%
LONG-TERM ASSETS
Property, Plant & Equipment $1.297M $630.0K
YoY Change 105.87% -60.38%
Goodwill
YoY Change
Intangibles $1.351M
YoY Change
Long-Term Investments
YoY Change
Other Assets $434.0K $448.0K
YoY Change -3.13% -48.51%
Total Long-Term Assets $2.973M $3.496M
YoY Change -14.96% -32.12%
TOTAL ASSETS
Total Short-Term Assets $3.046M $3.380M
Total Long-Term Assets $2.973M $3.496M
Total Assets $6.019M $6.876M
YoY Change -12.46% -20.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $512.0K $534.0K
YoY Change -4.12% -34.07%
Accrued Expenses $888.0K $718.0K
YoY Change 23.68% -42.56%
Deferred Revenue
YoY Change
Short-Term Debt $2.852M $2.395M
YoY Change 19.08%
Long-Term Debt Due $219.0K
YoY Change
Total Short-Term Liabilities $4.721M $4.205M
YoY Change 12.27% -5.93%
LONG-TERM LIABILITIES
Long-Term Debt $915.0K $0.00
YoY Change
Other Long-Term Liabilities $781.0K $1.214M
YoY Change -35.67% 20.2%
Total Long-Term Liabilities $1.696M $1.214M
YoY Change 39.7% 20.2%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.721M $4.205M
Total Long-Term Liabilities $1.696M $1.214M
Total Liabilities $6.417M $5.419M
YoY Change 18.42% -1.06%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.698M -$2.843M
YoY Change
Total Liabilities & Shareholders Equity $6.019M $6.876M
YoY Change -12.46% -20.63%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$599.0K -$373.0K
YoY Change 60.59% -58.83%
Depreciation, Depletion And Amortization $66.00K $63.00K
YoY Change 4.76% -12.5%
Cash From Operating Activities -$394.0K $265.0K
YoY Change -248.68% -177.71%
INVESTING ACTIVITIES
Capital Expenditures -$2.000K $3.000K
YoY Change -166.67% -94.83%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.000K -$41.00K
YoY Change -95.12% -65.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 824.0K
YoY Change
NET CHANGE
Cash From Operating Activities -394.0K 265.0K
Cash From Investing Activities -2.000K -41.00K
Cash From Financing Activities 824.0K
Net Change In Cash 428.0K 224.0K
YoY Change 91.07% -148.7%
FREE CASH FLOW
Cash From Operating Activities -$394.0K $265.0K
Capital Expenditures -$2.000K $3.000K
Free Cash Flow -$392.0K $262.0K
YoY Change -249.62% -165.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 isco Paycheck Protection Program Loan Current
PaycheckProtectionProgramLoanCurrent
141000
CY2020Q4 isco Paycheck Protection Program Loan Noncurrent
PaycheckProtectionProgramLoanNoncurrent
517000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-373000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
63000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
418000
CY2020Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
25000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-377000
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-129000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
227000
CY2020Q1 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-17000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-120000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
76000
CY2020Q1 isco Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-81000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
265000
CY2021Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
824000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
428000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
224000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
689000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
484000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1117000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
708000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
2000
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
421000
CY2021Q1 isco Patent License Costs Included In Accrued Liabilities
PatentLicenseCostsIncludedInAccruedLiabilities
2000
CY2021Q1 us-gaap Interest Expense
InterestExpense
32000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-32000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-599000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7539000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
234000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-2843000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-599000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
66000
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
69000
CY2020Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
71000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
234000
CY2021Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
27000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
34000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
151000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
263000
CY2021Q1 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-13000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
152000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
174000
CY2021Q1 isco Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-82000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-394000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000
CY2020Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
38000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41000
CY2021Q1 isco Proceeds From Paycheck Protection Program Loan Amount
ProceedsFromPaycheckProtectionProgramLoanAmount
474000
CY2021Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
350000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
3000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying condensed consolidated financial statements. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values, allowance for excess and obsolete inventories, allowance for sales returns and doubtful accounts, and the fair value of stock option grants using the Black-Scholes option valuation model. Actual results could differ from those estimates.</p>
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Customer Concentrations</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2021 and 2020, for the biomedical market segment, one customer accounted for approximately 40% and 49%, respectively, of consolidated revenues. As of March 31, 2021 and December 31, 2020, the customer accounted for approximately 48% and 55%, respectively, of accounts receivable, net. No other single customer accounted for more than 10% of revenues for the periods then ended for any segment.</p>
CY2021Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2021Q1 isco Number Of Business Units
NumberOfBusinessUnits
2
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12000
CY2008Q2 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
CY2008Q2 isco Specified Amount Of Revenue To Be Utilized First For Advances
SpecifiedAmountOfRevenueToBeUtilizedFirstForAdvances
250000
CY2021Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
CY2021Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P15Y
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2021Q1 isco Number Of Products Categories
NumberOfProductsCategories
2
CY2021Q1 isco Number Of Sales Channels
NumberOfSalesChannels
2
CY2021Q1 us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
The Company's revenue consists primarily of sales of products from its two revenue-generating operating segments, the biomedical products market and anti-aging products market business segments. The biomedical market segment markets and sells primary human cell research products with two product categories, cells and media, which are sold both domestically within the United States and internationally. The anti-aging market segment markets and sells a line of skincare products sold through two sales channels: ecommerce and professional. The ecommerce channel sells direct to customers through online orders, while professional sales are to spas, salons and other skincare providers.
CY2021Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2020Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021Q1 isco Product Return Guarantee Period
ProductReturnGuaranteePeriod
P30D
CY2021Q1 isco Allowance For Sales Return
AllowanceForSalesReturn
0
CY2020 isco Allowance For Sales Return
AllowanceForSalesReturn
0
CY2021Q1 isco Financial Assets Fair Value Disclosure
FinancialAssetsFairValueDisclosure
0
CY2021Q1 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10358035
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14920910
CY2021Q1 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
CY2021Q1 us-gaap Change In Accounting Principle Accounting Standards Update Adoption Date
ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
2021-01-01
CY2021Q1 us-gaap Change In Accounting Principle Accounting Standards Update Immaterial Effect
ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
true
CY2021Q1 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201912Member
CY2021Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
475000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
427000
CY2021Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
596000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
481000
CY2021Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
950000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
991000
CY2021Q1 us-gaap Inventory Gross
InventoryGross
2021000
CY2020Q4 us-gaap Inventory Gross
InventoryGross
1899000
CY2021Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
582000
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
611000
CY2021Q1 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1439000
CY2020Q4 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1288000
CY2021Q1 us-gaap Inventory Write Down
InventoryWriteDown
44000
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3438000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3438000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2946000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2904000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
42000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
41000
CY2021Q1 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
2290000
CY2021Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1123000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1099000
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1167000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1187000
CY2021Q1 isco Indefinite Life Logos And Trademarks
IndefiniteLifeLogosAndTrademarks
75000
CY2020Q4 isco Indefinite Life Logos And Trademarks
IndefiniteLifeLogosAndTrademarks
75000
CY2020Q2 isco Paycheck Protection Program Loan Maturity Period
PaycheckProtectionProgramLoanMaturityPeriod
P2Y
CY2020Q2 isco Paycheck Protection Program Loan Interest Rate
PaycheckProtectionProgramLoanInterestRate
0.01
CY2021Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1242000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1262000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24000
CY2020Q2 isco Paycheck Protection Program Loan Deferred Payment Period
PaycheckProtectionProgramLoanDeferredPaymentPeriod
P10M
CY2020Q2 isco Paycheck Protection Program Loan Forgiveness Period
PaycheckProtectionProgramLoanForgivenessPeriod
P168D
CY2021Q1 isco Cares Act Of2020 Aid Amount
CARESActOf2020AidAmount
474000
CY2021Q1 isco Paycheck Protection Program Loan Maturity Period
PaycheckProtectionProgramLoanMaturityPeriod
P5Y
CY2021Q1 isco Paycheck Protection Program Loan Interest Rate
PaycheckProtectionProgramLoanInterestRate
0.01
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
22000
CY2020Q2 isco Cares Act Of2020 Aid Amount
CARESActOf2020AidAmount
654000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 isco Class Of Warrant Or Right Issued Exercisable For Shares Of Common Stock
ClassOfWarrantOrRightIssuedExercisableForSharesOfCommonStock
62047
CY2016Q1 isco Class Of Warrant Or Right Issued Exercisable For Shares Of Common Stock
ClassOfWarrantOrRightIssuedExercisableForSharesOfCommonStock
11159995
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
233000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
240000
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.75
CY2016Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.75
CY2021Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15668753
CY2021Q1 isco Related Party Rent Expense
RelatedPartyRentExpense
43000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1109000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
118000
CY2020Q1 isco Related Party Rent Expense
RelatedPartyRentExpense
41000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
234000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
418000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
326000
CY2021Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
350000
CY2021Q1 isco Number Of Operating Leases
NumberOfOperatingLeases
3
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
118000
CY2021Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
387000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
394000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
255000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1509000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
400000

Files In Submission

Name View Source Status
0001564590-21-027997-index-headers.html Edgar Link pending
0001564590-21-027997-index.html Edgar Link pending
0001564590-21-027997.txt Edgar Link pending
0001564590-21-027997-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
isco-10q_20210331.htm Edgar Link pending
isco-20210331.xml Edgar Link completed
isco-20210331.xsd Edgar Link pending
isco-20210331_cal.xml Edgar Link unprocessable
isco-20210331_def.xml Edgar Link unprocessable
isco-20210331_lab.xml Edgar Link unprocessable
isco-20210331_pre.xml Edgar Link unprocessable
isco-ex311_8.htm Edgar Link pending
isco-ex312_6.htm Edgar Link pending
isco-ex321_9.htm Edgar Link pending
isco-ex322_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending